

Friedreich Ataxia Pipeline Report, 2023- Planned Drugs by Phase, Mechanism of Action, Route of Administration, Type of Molecule, Market Trends, Developments, and Companies

https://marketpublishers.com/r/FD25489F7836EN.html

Date: February 2023

Pages: 140

Price: US\$ 2,100.00 (Single User License)

ID: FD25489F7836EN

Abstracts

Friedreich Ataxia Pipeline Report is a comprehensive report on the pre-clinical and clinical stage pipeline candidates under development as of H1 2023. For each of the Friedreich Ataxia pipeline candidate, details of leading companies, phase of development, mechanism of action, route of administration, molecule type, and other critical information is provided. In addition, recent Friedreich Ataxia market trends, developments, and other market updates are provided in the Friedreich Ataxia pipeline study.

The global Friedreich Ataxia industry is characterized by a robust pipeline. The report estimates a promising pipeline for Friedreich Ataxia between 2023 and 2030. Further, emerging companies play an important role in the global share of the Friedreich Ataxia pipeline. It is developed through intense primary and secondary research including discussions with pharmaceutical company executives and members of industry associations and other industry stakeholders.

Overview of Friedreich Ataxia Drug Development Pipeline: 2023 Update
The Friedreich Ataxia condition has one of the most promising pipelines with the
presence of a large number of pharmaceutical companies. Amidst significant unmet
market potential for Friedreich Ataxia, several small and large-scale companies are
investing in advancing their pipeline candidates into advanced phases.

The current Friedreich Ataxia pipeline study examines the state of the drug pipeline and provides insights into the global vitiligo industry. A complete pipeline review of the



current treatments and therapies being developed for Friedreich Ataxia, Data, and insights into pipeline candidates including a detailed overview of the highlighted target and drug characteristics, companies, and developments are included.

Looking Ahead: 2023 Friedreich Ataxia Pipeline Analysis and Outlook
This quarterly updated report provides data and critical insights into the current pipeline
of therapeutic candidates in development with the potential to address Friedreich
Ataxia. The current status of each of the Friedreich Ataxia drug pipeline candidates is
provided in the study. In addition, developing and licensing/partner companies,
originators, alternative drug names, special status, phase, trial details, route, target,
molecule type, and others are provided in the study.

Preclinical Friedreich Ataxia Pipeline Drugs

The global vitiligo therapeutic pipeline is characterized by a significant number of drug candidates in the preclinical drug discovery and research phases. Driven by robust market growth prospects for Friedreich Ataxia therapeutic drugs, a large number of companies are investing in the preclinical Friedreich Ataxia pipeline. The report provides the current status and other developments of each drug candidate.

Clinical Phase Friedreich Ataxia Pipeline Drugs

The report showcases the pipeline candidates currently underway focusing on medications that are in Phase I, Phase I/II, Phase II, Phase II/III, and Phase III stages of development. The chapter presents the number of projects in clinical development by pipeline phase.

Friedreich Ataxia Clinical Trials Landscape

The report provides in-depth information on the Friedreich Ataxia clinical trials of each pipeline product. To support pharmaceutical companies to understand the suitable countries for clinical trials, study types, and other parameters to minimize complexity and increase success rates, the report offers details of all potential clinical trials.

Friedreich Ataxia companies in Pipeline

Amidst growth in R&D investment, pharmaceutical companies increasingly emphasize strengthening their pipeline product portfolio to ensure time-efficient drug developments. The Friedreich Ataxia pipeline assessment report provides details of drug companies, originators, licensing and collaborating partners, and others involved in the Friedreich Ataxia pipeline industry.

Market Developments



The report offers recent market news and developments in the Friedreich Ataxia markets. To support companies developing innovative therapies in both the preclinical and clinical stages of development, the chapter provides recent deals, mergers, and development news in the industry.

Scope of the Report

An introduction to the Friedreich Ataxia disease, diagnosis, and therapeutic snapshots including available options and the companies involved in the industry

Analysis of Friedreich Ataxia drugs in the preclinical phase of development including discovery and research

Most promising Friedreich Ataxia drugs in the clinical stage of development including phase 1, phase 2, and phase 3

Leading companies investing in the Friedreich Ataxia drug development pipeline Friedreich Ataxia pipeline drug details-

Drug name and alternative names

Current status of the pipeline candidate

Route of administration

Mechanism of Action

Molecule type

Clinical trials completed and ongoing

Companies involved in the development, technology providers,

licensing/collaborations, etc.

Business profiles of leading Friedreich Ataxia companies

Recent Friedreich Ataxia market news and developments



Contents

1. FRIEDREICH ATAXIA PIPELINE ASSESSMENT, 2023

- 1.1 Friedreich Ataxia Pipeline Snapshot
- 1.2 Companies investing in the Friedreich Ataxia industry

2 LOOKING AHEAD: OUTLOOK OF THE GLOBAL FRIEDREICH ATAXIA PIPELINE FROM 2023 TO 2030

- 2.1 Friedreich Ataxia Drugs by Phase of Development
- 2.2 Friedreich Ataxia Drugs by Mechanism of Action
- 2.3 Friedreich Ataxia Drugs by Route of Administration
- 2.4 Friedreich Ataxia Drugs by New Molecular Entity
- 2.5 Friedreich Ataxia Drugs by Companies, Universities, and Institutes

3. DRUG PROFILES OF FRIEDREICH ATAXIA PRECLINICAL PIPELINE CANDIDATES

- 3.1 Current Status of Friedreich Ataxia Drug Candidates, 2023
- 3.2 Preclinical Friedreich Ataxia Drug Snapshots

4. DRUG PROFILES OF FRIEDREICH ATAXIA CLINICAL PIPELINE CANDIDATES

- 4.1 Current Status of Friedreich Ataxia Drug Candidates, 2023
- 4.2 Friedreich Ataxia Drugs in Development- Originator/Licensor
- 4.3 Friedreich Ataxia Drugs in Development- Route of Administration
- 4.4 Friedreich Ataxia Drugs in Development- New Molecular Entity (NME)

5. FRIEDREICH ATAXIA CLINICAL TRIALS ANALYSIS

- 5.1 Preclinical Trial Snapshots
- 5.2 Phase 1 Clinical Trial Snapshots
- 5.3 Phase 2 Clinical Trial Snapshots
- 5.4 Phase 3 Clinical Trial Snapshots

6. FRIEDREICH ATAXIA PIPELINE COMPANIES ACTIVE IN 2023

6.1 Leading Friedreich Ataxia companies investing in new drug development



- 6.1.1 Company Business Description
- 6.1.2 Company Pipeline snapshot
- 6.2 Leading Friedreich Ataxia Universities/Institutes researching drug development

7. FRIEDREICH ATAXIA MARKET NEWS AND DEVELOPMENTS

- 7.1 Recent Friedreich Ataxia Developments
- 7.2 Friedreich Ataxia Pipeline News

8. APPENDIX

- 8.1 Sources and Research Methodology
- 8.2 Customization options
- 8.3 Legal Disclaimer



I would like to order

Product name: Friedreich Ataxia Pipeline Report, 2023- Planned Drugs by Phase, Mechanism of Action,

Route of Administration, Type of Molecule, Market Trends, Developments, and

Companies

Product link: https://marketpublishers.com/r/FD25489F7836EN.html

Price: US\$ 2,100.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/FD25489F7836EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

| First name: | |
|---------------|---------------------------|
| Last name: | |
| Email: | |
| Company: | |
| Address: | |
| City: | |
| Zip code: | |
| Country: | |
| Tel: | |
| Fax: | |
| Your message: | |
| | |
| | |
| | |
| | **All fields are required |
| | Custumer signature |
| | |
| | |

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below



and fax the completed form to +44 20 7900 3970